We are pleased to announce that Navigator Capital Group acted as a sole financial advisor to Selvita S.A in the acquisition process of 100% of shares in Fidelta, significant CRO (contact research organization) based in Zagreb, Croatia from Galapagos NV for an enterprise value of € 31.2 M.

Selvita is a preclinical Contract Research Organization providing multidisciplinary support within the area of drug discovery, regulatory studies, as well as research and development. The Company is listed on the Warsaw Stock Exchange and currently employs over 550 professionals. The acquired company, Fidelta, provides services complementary to Selvita’s offerings and will strengthen the market position and competitive advantage of Selvita.

The seller, Galapagos NV, is a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines.

The project was led by Karol Szykowny, CFA (Director) supported by Artur Wilk (Manager) and Pandion Partner from Croatia, Tomislav Kovalisko.

We also extend our thanks to our counterparts from Kempen & Co team, Remco Lont for cooperation on this project.

 We would like to congratulate the Management of Selvita as well as the Fidelta team and wish them all the best in further dynamic growth in Europe and beyond.